GlobalData
Shaping AML treatment: how menin inhibitors are changing the game
The menin inhibitors revumenib and ziftomenib are in close competition for a share of the acute myeloid leukaemia (AML) market.
Rivaroxaban reduces adverse kidney events in atrial fibrillation patients with CKD
Wastewater surveillance should be used to detect viral outbreaks in schools
30 years of failed trials put sepsis on track to be the main cause of death by 2050
Reduced pulmonary vascular resistance demonstrated in A DUE study
The state of the oncology microbiome therapeutics pipeline at a glance
More positive data for Daiichi Sankyo and AstraZeneca’s blockbuster drug Enhertu
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
